LINK strengthens Board with appointment of Marc Lemaître
LINK has announced the appointment of Dr Marc Lemaître to its company board as a non-executive Director. Dr Lemaître brings to LINK his extensive experience in the nucleic acids field, supporting LINK’s strategic direction in developing both its established nucleic acid reagents business and its growing range of innovative reagents for oligo therapeutics and diagnostics.
Since obtaining a PhD in Biochemistry from the University of Liège, Dr Lemaître has been working in the field of nucleic acids for over 25 years, holding senior positions within various high profile CMOs, Pharma and Biotech companies. Notably, he oversaw the implementation of IVD oligo production at Eurogentec, SA during 13 years with the company. Based in the USA since 2006, Marc worked for Glen Research before being appointed in 2009 as CEO of Girindus America, a CMO with a focus on the cGMP manufacture of oligonucleotides for therapeutic applications. Whilst there he also acted as President of Girindus AG. Since negotiating the merger between Nitto-Denko Avecia and the US operations of Girindus in 2013, Marc has been working as an independent consultant.
Other news from the department people
